Parvis raises financing with full warrants and convertible structure

Board members are participating in the financing alongside investors as Parvis expands across the U.S. and Canada Vancouver, British Columbia--(Newsfile Corp. - June 30, 2026) - Parvis Invest Inc. (TSXV: PVIS) ("Parvis" or the "Company"), a technology-driven platform for private alternative investments, today announced an amendment to its previously announced concurrent financing (the "Concurrent Financing"). The Concurrent Financing, originally structured as a non-brokered private placement of equity units, has been amended to consist of unsecured convertible debentures (the "Debentures") to raise gross proceeds of up to C$3,000,000. All other material terms of the Concurrent Financing remain unchanged, including the offering price of C$0.55 per Debenture unit and the warrant exercise price of C$0.65.

The Concurrent Financing is being undertaken in connection with the Company's previously announced binding letter of intent to acquire Atlas One Digital Securities Inc. ("Atlas One") and its signed share purchase agreement to acquire FavorPoint Capital, LLC ("FavorPoint"), a FINRA-registered U.S. broker-dealer. Use of Concurrent Financing Proceeds Concurrent Financing is a component of Parvis's broader North American expansion strategy, through which the Company is building a fully integrated private markets platform operating across both Canadian and U.S. capital markets. Net proceeds will be directed toward the integration of Atlas One, the acquisition and integration of FavorPoint onto the Parvis platform through the FINRA Continuing Membership Application process, and working capital to support the general and administrative expenses of the Company.

Details of the Amended Concurrent Financing The Concurrent Financing, as amended, consists of unsecured convertible debentures with an aggregate principal amount of up to C$3,000,000, at a subscription price of C$0.55 per unit. Each unit of Debenture consists of C$0.55 in principal amount and one (1) whole common share purchase warrant (amended from one-half of one warrant). Each whole warrant is exercisable to acquire one common share at a price of C$0.65 for a period of 24 months from the date of closing.

The Debentures will bear interest at 10% per annum, will mature 24 months from closing, and will be convertible into common shares at the option of the holder at a conversion price of C$0.55 per share. The offering is anticipated to close on or about July 31, 2026, subject to TSX Venture Exchange acceptance and satisfaction of customary closing conditions. All securities issued will be subject to a statutory hold period of four months and one day from the closing date.

The proposed offering price remains subject to Exchange acceptance. Board Participation The Company is pleased to announce that certain members of its Board of Directors intend to participate in the Concurrent Financing by subscribing for Debentures on the same terms as other investors. Board participation reflects the directors' continued confidence in the Company's strategic direction and their alignment with shareholders as Parvis executes on its North American expansion.